Table 1.
Patient characteristics, neoadjuvant treatments, operative details, and tumor characteristics.
| Characteristics | Overall Cohort (n = 182) | |
|---|---|---|
| Patient characteristics | ||
| Age, y | 62 (15.0) | |
| Sex | ||
| Male | 135 (74.2) | |
| Female | 47 (25.8) | |
| Height, m | 1.7 (0.1) | |
| CCI | ||
| 2 | 122 (67.0) | |
| ≥3 | 60 (33.0) | |
| Clinical stage | ||
| II | 46 (25.3) | |
| III–IV | 136 (74.7) | |
| Before NT | ||
| Body weight, kg | 67.4 (10.6) | |
| BMI, kg/m2 | ||
| <18.5 | 7 (3.8) | |
| 18.5–22.9 | 71 (39.0) | |
| 23–24.9 | 45 (24.8) | |
| ≥25 | 59 (32.4) | |
| NRS2002 | ||
| <3 | 100 (54.9) | |
| ≥3 | 82 (45.1) | |
| NLR | ||
| ≤3 | 144 (79.1) | |
| >3 | 38 (20.9) | |
| Serum PA, mg/L | ||
| <200 | 46 (25.3) | |
| ≥200 | 136 (74.7) | |
| After NT | ||
| Body weight, kg | 66 (15.3) | |
| BMI, kg/m2 | ||
| <18.5 | 8 (4.4) | |
| 18.5–22.9 | 71 (39.0) | |
| 23–24.9 | 44 (24.2) | |
| ≥25 | 59 (32.4) | |
| NRS2002 | ||
| <3 | 116 (63.7) | |
| ≥3 | 66 (36.3) | |
| NLR | ||
| ≤3 | 149 (81.9) | |
| >3 | 33 (18.1) | |
| Serum PA, mg/L | ||
| <200 | 43 (23.6) | |
| ≥200 | 139 (76.4) | |
| Neoadjuvant treatments | ||
| NT scheme | ||
| NAC | 147 (80.8) | |
| NCRT | 35 (19.2) | |
| NAC regimen | ||
| SOX | 172 (94.5) | |
| XELOX/FOLFOX | 10 (5.5) | |
| Operations performed | ||
| Type of resection | ||
| Total gastrectomy | 87 (47.8) | |
| Distal gastrectomy | 91 (50.0) | |
| Proximal gastrectomy | 4 (2.2) | |
| Type of reconstruction | ||
| Roux-en-Y | 106 (58.2) | |
| Billroth I | 76 (41.8) | |
| Tumor characteristics | ||
| Tumor location | ||
| Upper | 42 (23.1) | |
| Middle | 46 (25.3) | |
| Lower | 94 (51.6) | |
| ypstage | ||
| 0 | 29 (15.9) | |
| I | 63 (34.7) | |
| II | 45 (24.7) | |
| III | 45 (24.7) | |
| CAP-TRG | ||
| 0 | 29 (15.9) | |
| 1 | 19 (10.4) | |
| 2 | 70 (38.5) | |
| 3 | 64 (35.2) | |
Abbreviations: CCI, Charlson comorbidity index; NT, neoadjuvant treatment; BMI, body mass index; NRS2002, the Nutritional Risk Screening 2002; NLR, Neutrophil-lymphocyte ratio; Serum PA, Serum prealbumin; NAC, neoadjuvant chemotherapy; NCRT, neoadjuvant chemoradiotherapy; ypstage, post-neoadjuvant therapy stage; CAP, College of American Pathologists; TRG, tumor regression grading. - Values for continuous variables are given as mean (standard deviation) or median (interquartile range). Categorical variables are expressed as numbers (percentages).